INTRODUCTION
Care for related stem cell donors is heterogeneous. While World Marrow Donor Association (WMDA) Standards 1 ensure consistency in the assessment and care of unrelated donors (UDs), no such criteria exist for related donors (RDs). Several parties have highlighted discrepancies between the clear standards of care for unrelated donors and those for RDs. [2] [3] [4] [5] Specific issues include potential conflicts of interest (when the same team is involved in the care of the RD and their recipient), the absence of standardized related donor (medical) suitability criteria, and the lack of centralized adverse event recording and donor follow-up in the RD setting.
Recent changes to JACIE/FACT standards 6 addressed some of these points, with stipulations that 'allogeneic donor suitability should be evaluated by a licensed health-care professional who is not the primary transplant physician or health-care professional overseeing care of the recipient', and that all donors are offered follow-up. Guidance in this area has also been produced by other organizations. In 2010, the Ethics Working Group and the Clinical Working Group of the WMDA formed a subcommittee, which established recommendations for family donor care. 4 A joint effort of the EBMT Late Effects working party and WMDA resulted in Donor Outcome workshops, and, in 2013, a consensus paper on standardized assessment of donor outcome 7 was published under the umbrella of Worldwide Network for Blood and Marrow Transplantation (WBMT).
Implementation of the above guidance is impossible without major changes from the historical set up of RD care, where the same team of transplant physicians would have responsibility for both the RD and their hematopoietic progenitor cell (HPC) recipient. The changes to practice required to meet regulatory standards will increase the burden of RD care on TCs, as could the potential growth in haploidentical transplantation. In some countries, this situation has been addressed by UD registries undertaking roles in the RD care pathway. Consideration of this issue at an international level led to a debate at EBMT annual meeting in 2013, discussing the potential role for UD registries in the management of related donors. Here we examine the arguments raised for and against registry involvement in RD care and describe international experience of alternative pathways.
ARE UD REGISTRIES AND RDS A GOOD FIT?
Considering the substantial overlap in components of care required to manage RD and UD, donor registries would seem well placed to undertake the management of RDs. From donor medical evaluation to donation and follow-up, validated registry procedures are in place for each stage of the donor pathway. Although inherent differences exist between UDs and RDs, many existing procedures could be adapted to meet the needs of RDs.
It should be noted that several UD registry functions are not relevant in the RD context. For instance, registries must recruit and retain a large, diverse panel of donors, and develop specialized search services and algorithms. In the case of RDs, who are identified by their families, many of these primary functions are unnecessary, and the fit between RDs and HPC donor registries is by no means exact. Furthermore, the way that UD registries and their collection centers operate varies from country to country; for this reason is it unlikely that a single universal model of UD registry management of RDs is possible, instead national models of successful RD care will need to be tailored to the set up of their registry and transplant centers.
WOULD RD SAFETY BE IMPROVED BY DONOR REGISTRY INVOLVEMENT?
There are indications that HPC donation is less safe for RDs than UDs. A retrospective EBMT study by Halter et al. 8 described five donor deaths within 30 days of donation in 36 317 family donations between 1993 and 2005. One death was unequivocally linked to the donation, due to erroneous infusion of i.v. fluid. Other deaths were caused by subarachnoid hemorrhage in a donor on aspirin, a massive pulmonary embolus 15 days after donation and two deaths due to cardiac arrest with no further details available. During the same time period no deaths occurred in 14 706 donations from volunteer UDs. One unrelated donor death has since been reported to the central reporting system of the WMDA member organizations (S(P)EAR committee), caused by a hemothorax secondary to traumatic subclavian line insertion.
Additional deaths in RDs have been reported, 9 one due to sickle crisis in a PBSC donor, others due to respiratory or cardiac arrest. The lack of mandatory SAE reporting in the RD setting makes it difficult to speculate on true incidence of these events, and the causal relationship with donation is hard to assess retrospectively. As the majority of fatal and serious adverse events have occurred in donors with pre-existing medical issues, it is very likely that robust donor assessment procedures will reduce fatal complications.
Where written criteria for RD suitability are employed, they are varied and tend to be less stringent than UD criteria. A survey in Italy 5 found that only 26.4% donors underwent thorough screening according to Italian Bone Marrow Donor Registry standard, and both Wiersum et al. 10 and Kodera et al. 11 found increased adverse events in donors not meeting UD suitability criteria.
To minimize risks to donor health and reduce deferral rates at the point of donor medical examination, an initial assessment of RD health should be performed before tissue typing. Medical suitability criteria for RDs should ideally be standardized; 4 adjustment of specific criteria for RDs is likely to be a subject for further discussion and may lead to increased RD deferral rates.
There are no data from which we can conclude that RD health would be better protected by UD registry care, but given the extensive experience that registries have in performing donor health evaluations, there is a justification for considering that the health of RDs would be well preserved, with greater uniformity, if health assessments were undertaken by experienced registry physicians.
A potential issue with the approach of RD evaluation by donor registries lies in the fact that suitability criteria in the UD setting are applied in a strict manner. There is provision for some flexibility with respect to recipient risk (the recipient's transplant physician is consulted in cases of unclear/minimal recipient risk, abrogated by the urgency of the transplant), but suitability criteria are less flexible regarding donor risk. The reason for this policy is that in some cases there is insufficient evidence to estimate an increased risk to the donor.
THE ISSUE OF DONOR'S INFORMED CONSENT
For UDs we take a conservative stance with respect to any potential or theoretical risk. The correct approach to obtaining informed consent from RDs in these gray areas is more contentious. One could argue that it is inappropriate to ask a family donor to accept any additional risk and that medical selection criteria should be identical for RDs and UDs to avoid a disparity in treatment. This approach is employed in solid organ donation, but the risk/benefit ratio in HPC donation may be different. Here the risks of the donation procedure are usually minimal, and a RD with a close bond to the respective recipient has a potential psychological benefit to gain from a donation leading to a successful transplant outcome. 12 An alternative viewpoint, therefore, is that in situations where the risks to the donor are minimally/theoretically increased, this risk must be balanced against the psychological benefit. The donor would require a comprehensive discussion of potential risks, and additional consent may be necessary for some 'theoretical donor safety' issues. In particularly complex cases, consultation with a panel of experts may be prudent.
WILL WORKING THROUGH REGISTRY NETWORKS IMPROVE BM HARVESTS?
The last two decades have seen a continuing increase in the proportion of donors undergoing PBSC donation, rather than BM harvest. As a result, some transplant centers now perform very few BM harvests, and, despite fulfilling JACIE/FACT requirements for one procedure per year, 6 it can be difficult for staff to remain skilled. This raises concerns with both maintaining the BM harvest quality and preserving donor health. It seems rational for harvests to be restricted to centers facilitating sufficient donors that the procedure is performed regularly. Registries and their affiliated collection centers tend to perform the largest numbers of marrow harvests, and, as the increase in PBSC donors continues, the safety and efficacy of BM harvesting may be greatest if performed by UD registries.
DONOR ADVOCACY
To avoid a conflict of interest, the medical evaluation of an unrelated donor is never conducted by a physician in the transplant team caring for the patient. 1 This practice, along with the stipulation that registries must have systems in place to maintain confidentiality, ensures that UDs are not subject to coercion. 13, 14 In contrast, RDs are frequently managed by transplant physicians in the same team as that caring for the recipient. O'Donnell et al. 3 found that, in over 70% centers in the United States, the physician assessing a RD either had simultaneous responsibility for, or might be involved in the care of, the recipient. In all, 52% of respondents of an EBMT nurses group survey 2 indicated that donors in their center were consented by transplant doctors compared with a quarter who indicated that consent was obtained by doctors un-connected with the transplant team. In 2012, a survey of Italian transplant centers 5 reported that, in four of nine centers, the same physician managed donors and recipients, with peri-donation care provided by transplant physicians in six of nine centers. Furthermore, it is unclear to what extent RDs are given the choice between donation routes in this setting or whether their consent is truly voluntary.
The need for independent evaluation and donor advocacy has long been recognized by the solid organ transplant community, 15 and processes to prevent conflicts of interest have been developed while managing donors and recipients within the same center. This should also be achievable in HPC donation, particularly since donor care can be delivered by non-transplant physicians.
It is also necessary to consider intrinsic differences in the requirements of UDs and RDs. While registries have an independent donor advocate, it must be assured that this individual has appropriate experience to deal with the more complex issues around related donation (which may require additional training).
COULD REGISTRIES MANAGE PEDIATRIC RDS?
Stem cell donor registries have no experience managing donors under 16 or 18 years of age. Although medical suitability criteria, independent assessment and donor follow-up are equally important in the pediatric setting, there are additional unique issues to consider, such as the legal issues around parental 16, 17 Most current registry procedures would be unsuitable for pediatric donors, and additional study and consultation with affected parties are required to address this issue. Until this happens, the authors do not recommend that registries be involved in pre or peri-donation care of pediatric donors. Alternative options for pediatric donor care, outside of transplant centers, may be possible, but are beyond the scope of this paper.
An area in which UD registries could have a role in pediatric donor care immediately lies in provision of post-donation follow-up. Several parties have stressed the importance of longterm follow-up of pediatric donors, 16, 18 which is not currently performed and long-term monitoring becomes even more necessary if children are treated with G-CSF. 17, 19 
COULD DONOR REGISTRIES MEET THE PSYCHOLOGICAL NEEDS OF RDS?
The management of family donors must specifically address psychological as well as physical well-being. Donation can be a positive experience for HPC donors; 20 however, a significant proportion of RDs reports some psychological difficulty with the donation process, particularly if their recipient dies or develops GVHD.
12,21 Some studies of live renal donors have shown 410% donors reporting suicidal thoughts if their recipient experiences graft failure or dies. 22 In the live renal donor setting, it is recommended that all RDs undergo specific psychosocial evaluation, 23 a standard that should be extended to HPC donors. Since negative psychological impacts of HPC donation may manifest years post donation, it has been suggested that assessment of psychological well being should also extend to at least this time point, 12 and that psychological support should be available for donors life long.
When considering the potential psychological risks of donating to a relative, one must also consider the potential emotional distress to a relative of not having been a donor, either by choosing not to donate or after failing medical assessment.
UD registries and their affiliated collection centers may have no experience of dealing with the psychological aspects of donation to a relative, and the model of registry RD management becomes less logical if multiple new processes must be introduced to meet their needs. In contrast, transplant centers do not necessarily offer psychological support, and it may be preferable to RDs to discuss their worries or feelings with an individual who is independent of the transplant center (where their recipient may have died). As this will be a critical part of the evaluation and follow-up process, registries and their affiliated collection centers would need to ensure additional psychological expertize was available if they were managing related donors.
WOULD UNRELATED DONOR REGISTRIES PROVIDE BENEFIT TO THE FOLLOW-UP OF RDS?
Recent guidelines have focused on the importance of donor follow-up. In 2011, the NOTIFY report 24 recommended that any serious adverse reaction occurring between initiation of the donation procedure and 30 days after completion of the collection should be reported. The authors also recommended long-term follow-up of HPC donors on an annual or biannual basis for at least 10 years with assessment to include survival, new onset of hematologic or non-hematologic malignancy and new onset of autoimmune disease. In 2013 WBMT 7 made comparable recommendations for a standardized approach to prospective donor follow-up, which is again recognized in current JACIE standards. 6 In some countries, family donor registration and follow-up has become compulsory, while in others it remains limited. Clare et al. 2 reported 60% of respondents indicated that their center offered donor follow-up, 10% of whom had only limited follow-up provision. Coloccia et al. 5 found that, although all responding centers offered some donor follow-up, in only five of nine centers did this extend beyond 1 year after donation.
In the UD setting, long-term adverse event follow data are collected and reported globally to WMDA. Until recently no centralized data reporting existed for related donors, but since 2012 donor outcome forms have been implemented via the EBMT database under the guidance of the EBMT Donor Outcome committee in collaboration with the Swiss Transfusion SRC.
There is a clear rationale for long-term monitoring of RDs and UDs alike. Most published donor outcome data are derived from UDs who tend to be the healthiest donors; therefore, these findings cannot necessarily be translated to family donors. This becomes even more critical if in the future, alternative mobilizing agents such as biosimilar G-CSF or plerixafor are utilized. 7, 25 In the solid organ setting, follow-up is recognized as a vital duty to the donor to ensure no deterioration in organ function associated with donation, yet the same difficulties exist with respect to logistics and funding of follow-up. The difference with stem cell donation lies in the fact that no specific medical parameters require specialist monitoring and that accepted follow-up information can be collected by questionnaires.
Collecting and reporting these donor data can be logistically burdensome for TCs, and, since UD registries have follow-up procedures that can easily be extended to related donors, this appears a logical solution to achieve maximum donor data reporting.
Donors whose recipient has died may feel less inclined to establish contact for follow-up with the TC who cared for their recipient and may prefer contact from a registry. In contrast, some RDs may be less likely to comply with follow-up if it is performed by an organization with which they have no established relationship. The importance of follow-up would need to be stressed at the time of donor consent and consent obtained for transfer of donor data.
WHAT ARE THE FINANCIAL IMPLICATIONS OF DONOR REGISTRY INVOLVEMENT IN RD CARE?
Explicit funding for RD care is not universal at present and any alternative model of RD care will have financial implications. Donor registry provision of donor assessment or the donation procedure itself would likely be more expensive than current models; however, one must bear in mind that it would not be necessary to add costs clearly applicable only to UD activity (for example, donor recruitment/search).
Moreover, the cost of donation via an outside agency (such as a registry) should be weighed against the increased costs TCs would incur to meet emerging standards in this area. Donor selection and evaluation is a time consuming activity for TC personnel (estimated at a full week of work per donor). In the current economic climate where transplant centers are forced to cut costs, it is not unthinkable that UD use may decline, favoring haplo-identical donors. In Italy, a striking increase in the use of haplo-identical donors is seen, resulting in increasing numbers of transplantations and decreasing costs. In this situation, management of RDs by the unrelated donor registry was proposed as being a win/win situation, reducing the burden for transplant centers, but with considerably reduced costs to using an unrelated donor.
In most countries, donors (both hematopoietic and solid organ) must meet their own travel or accommodation costs to donate. For HPC donors, a choice of registry-affiliated collection centers could present a more convenient and less expensive option for donors in this regard.
Many countries have no financial provision for RD follow-up, which must to be incorporated into transplant costs regardless of which organization is responsible for follow-up. 7 CURRENT MODELS/EXPERIENCE OF RD MANAGEMENT BY DONOR REGISTRIES Assessment of related donors before HLA typing in Denmark In Denmark, related donors were originally managed by the medical team at the recipient's TC, where initial contact with RDs to arrange HLA typing was made by the TC physicians. The difficulty with this process lay in ensuring that RDs were managed confidentially, and that donation was entirely voluntary. Specific issues occurred when RDs were found to have medical issues precluding donation at the time of donor medical, or were unwilling to donate resulting in a delayed UD search.
In response to these issues, a new procedure was developed. Contact details for potential RDs are passed directly to the registry, who contact the RDs providing comprehensive information about donation and instructing them to contact the independent registry physician by telephone if they have any medical issues, wish to discuss donation or do not wish to donate. If the physician decides the relative is not fit to donate or they do not want to donate, HLA typing is not performed.
When the final HLA report is issued, a standard comment: 'Donor is not fit to donate based on information from donor' is written for every donor not HLA-typed, thus preserving confidentiality and voluntariness.
BM harvesting of RDs by the Europdonor Foundation and affiliated collection centres in the Netherlands
As the number of HPC donors undergoing BM harvest has declined, some TCs in the Netherlands have become unable to comply with JACIE Standards. Some TCs have therefore requested the Europdonor Foundation to undertake BM harvests on their RDs.
Europdonor Foundation performs the entire process of donor evaluation (using national guidelines for related donor screening, WMDA standards and NMDP medical assessment tools), donor clearance and the harvest procedure in one of their affiliated harvest centers. Europdonor Foundation and the harvesting centers are jointly responsible for RD follow-up of the referred donors, with data collection performed according to WBMT recommendations. 7 For the cost of donor care management, harvest and follow-up, Europdonor invoices the requesting TC (comparable to unrelated donor harvesting).
Standardized donor follow-up of Swiss Blood Stem Cells (SBSC) for related and unrelated donors Originally, unrelated donors in Switzerland were followed up by SBSC and regional transfusion services with follow-up costs included in the transplant lump sum, while their recipients TC followed up RDs, with funding provided by the recipient's health insurance (providing the patient remained alive).
In July 2007, the Transplantation Act 810.211 became effective in Switzerland, making donor follow-up mandatory for UDs and SDs. The SBSC and Swiss Blood Stem Cell Transplantation (SBST) (which supervises the scientific blood SCT activity in Switzerland, and therefore is responsible for RD follow-up) agreed to harmonize the process of donor follow-up.
The procedure for UD and RD donor follow-up is now as follows: 1 month post donation, donors attend a medical appointment at their collection center. At 6 months, 1 year and then every 2 years until 10 years post donation donors receive a questionnaire from the SBSC. The Transplantation Act prescribes life-long follow-up (to be reduced to 10 years next amendment). The data collected are based on the WBMT minimum data set 7 and are recorded in the EBMT registry database by SBSC. All donors sign informed consent for follow-up by SBSC and data transfer to EBMT.
At (first) RD or UD donation, an identical lump sum for the entire follow-up process is charged to the patient's health insurance, and transferred to a specific donor follow-up fund, from which all follow-up services are paid.
CONCLUSIONS
There is a clear need to standardize related donor assessment, harvest and follow-up procedures, to bring care in line with that of UDs. RD management by donor registries seems logical in many respects, offering an established structure for donor care, and extensive experience in the medical evaluation of donors. Certain components of RD care would be well served by existing registry processes, in particular there is a compelling argument for registry provision of centralized donor follow-up.
In other areas, such as the field of pediatric donation, additional expertize would be required before registries and their affiliated collection centers could feasibly facilitate donation. The continuing unmet needs of pediatric sibling donors have recently been highlighted, 26 and care pathways that address these needs should be explored.
For registries to provide appropriate evaluation for RDs, two specific issues will need to be addressed. First, the consideration for increased flexibility around medical criteria and second, the psychological aspects of related donation. Further consideration of how to cater to the psychological needs of RDs is warranted and evidence of sufficient psychological evaluation and support pre-and post donation would need to be demonstrated in any model of RD care.
Funding pathways and logistics of care differ between countries; for this reason there is probably no ideal 'one size fits all' model of related donor care.
Collaboration between transplant centers and registries is necessary to determine the best approach at a national level, which should also consider acceptability and convenience to related donors. A third option (other than donor care solely provided by a transplant center or UD registry) would be a 'middle pathway'. RDs could be managed by independent 'related donor hubs' offering the benefits of independent consent and experienced standardized evaluation, while specializing purely in related donors and ensuring their specific needs are met.
Whichever models are adopted, explicit funding for RD evaluation and follow-up must be built into transplant costs, if we are to reduce existing discrepancies in the care received by UDs and RDs.
